Do you enjoy working in the lab and have experience within formulation and analytical characterization of active pharmaceutical ingredients? Are you interested in developing liquid formulations for early in vivo studies? Do you thrive in a collaborative environment, working alongside highly motivated and skilled scientists? If so, join our Small Molecule Preformulation team within the Advanced Drug Delivery (ADD) function at AstraZeneca. This role is based in Gothenburg, Sweden and is part of our Pharmaceutical Sciences division. Accountabilities: Pharmaceutical Sciences at AstraZeneca delivers the therapies of the future through scientific leadership in drug delivery, design of synthetic routes, and manufacturing of Active Pharmaceutical Ingredients (API) and drug products. Our portfolio of projects spans traditional small molecules, peptides, oligonucleotides to RNA based therapeutics across AstraZeneca's therapy areas. Advanced Drug Delivery (ADD) resides within Pharmaceutical Sciences with a mission to provide novel drug products to AstraZeneca's clinical pipeline. As a Scientist in our team, you will support drug projects from the first in vivo studies to candidate drug nomination. Your focus will be on various small molecule projects where you will develop formulations for PK, PK/PD studies, and toxicology studies and support with analytical characterization. You will work as a member of pharmaceutical project teams, and in close collaboration with other analysts, formulators, solid state, biopharmaceutics experts in Pharmaceutical Sciences. Main Duties and Responsibilities * Develop suitable pre-clinical formulations or formulation methods for in vivo investigations to support drug development projects. * Perform essential characterization of the formulations e.g. content, stability, homogeneity, impurity, pH and particle size measurements. * Generate, evaluate, communicate, and report data clearly and reliably in accordance with current standard procedures. * Ensures own work is performed in accordance with appropriate Safety, Health & Environment (SHE), quality and compliance standards, e.g., Good Laboratory Practice (GLP) * Working as a member of cross-skilled drug development project teams. Essential Skills/Experience: * MSc degree in a scientific discipline relevant to analytical and formulation science (e.g., chemistry, pharmaceutical technology, or equivalent qualifications). * Basic knowledge of analytical methodologies such as spectrometry and separation science (U/HPLC) and basic understanding of liquid formulations. * Understanding of principles and applications of Good Laboratory Practices (GMP/GLP). * Ability to communicate in English, both orally and in writing. To be a successful candidate you should be experienced in analytical and/or formulation chemistry and preferably have previous exposure to an industrial setting. You should possess an enthusiasm for laboratory-based work with a passion for learning and implementing new techniques. We are looking for a scientist with good communication and planning skills, balanced with the ability to work independently. You will need a strong sense of responsibility, have excellent teamwork capability and be delivery focused. In addition, your flexibility and collaborative problem-solving mindset will secure your continued success on our team. Desirable Skills/Experience: * 3+ years of industrial experience of analytical and/or formulation work focused on small molecules in pre-clinical drug development phase. * Profound knowledge within liquid based formulation science as well as analytical chemistry. If your passion is science and you want to be part of a team that makes a bigger impact on patients' lives, then there's no better place to be. Join us at AstraZeneca where we truly understand science and apply it every day to strengthen and grow our pipeline. We are using our unique scientific capabilities to deliver what we believe to be one of the most productive pipelines in the industry. Ready to make a difference? Apply today! Welcome with your application no later than April 21st, 2024.